Thus the combination of 30fold higher approved dose and the double micromolar inhibition potency makes, in theory,
irbesartan 60 fold more potent to inhibit Hbv entry.
Of course, binding of these drugs to plasma proteins could cause substsntial differences in the available concentration on the hepatocyte membrane receptor, and the pharmacokinetics could further influence the in vivo efficscy.